Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Nov 1;71(11):635-638.
doi: 10.6061/clinics/2016(11)03.

Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome

Alexandre de Matos Soeiro  1 , Pedro Gabriel Melo de Barros E Silva  2 , Eduardo Alberto de Castro Roque  3 , Aline Siqueira Bossa  1 , Cindel Nogueira Zullino  1 , Sheila Aparecida Simões  2 , Mariana Yumi Okada  2 , Tatiana de Carvalho Andreucci Torres Leal  1 , Maria Carolina Feres de Almeida Soeiro  1 , Carlos V Serrano Jr  1 , Múcio Tavares Oliveira Jr  1
Affiliations
Observational Study

Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome

Alexandre de Matos Soeiro et al. Clinics (Sao Paulo). .

Abstract

Objectives:: Recent studies have revealed a relationship between beta-blocker use and worse prognosis in acute coronary syndrome, mainly due to a higher incidence of cardiogenic shock. However, the relevance of this relationship in the reperfusion era is unknown. The aim of this study was to analyze the outcomes of patients with acute coronary syndrome that started oral beta-blockers within the first 24 hours of hospital admission (group I) compared to patients who did not use oral beta-blockers in this timeframe (group II).

Methods:: This was an observational, retrospective and multicentric study with 2,553 patients (2,212 in group I and 341 in group II). Data regarding demographic characteristics, coronary treatment and medication use in the hospital were obtained. The primary endpoint was in-hospital all-cause mortality. The groups were compared by ANOVA and the chi-square test. Multivariate analysis was conducted by logistic regression and results were considered significant when p<0.05.

Results:: Significant differences were observed between the groups in the use of angiotensin-converting enzyme inhibitors, enoxaparin, and statins; creatinine levels; ejection fraction; tabagism; age; and previous coronary artery bypass graft. Significant differences were also observed between the groups in mortality (2.67% vs 9.09%, OR=0.35, p=0.02) and major adverse cardiovascular events (11% vs 29.5%, OR=4.55, p=0.02).

Conclusions:: Patients with acute coronary syndrome who underwent early intervention with oral beta-blockers during the first 24 hours of hospital admission had a lower in-hospital death rate and experienced fewer major adverse cardiovascular events with no increase in cardiogenic shock or sustained ventricular arrhythmias compared to patients who did not receive oral beta-blockers within this timeframe.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported.

References

    1. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127((4)):e362–e425. doi: 10.1161/CIR.0b013e3182742cf6. - DOI - PubMed
    1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr, Ganiats TG, Holmes DR, Jr, et al. 2014 AHA/ACC guideline for the management of patients with non&ndash;ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130((25)):e344–426. doi: 10.1161/CIR.0000000000000134. - DOI - PubMed
    1. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127((10)):939–53. doi: 10.1016/j.amjmed.2014.05.032. - DOI - PubMed
    1. Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Rosenberg Y, O'Rourke R, et al. beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. Am Heart J. 2010;160((3)):435–442.e1. doi: 10.1016/j.ahj.2010.06.023. - DOI - PMC - PubMed
    1. Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62((19)):1791–801. doi: 10.1016/j.jacc.2013.04.102. - DOI - PMC - PubMed

Publication types

Substances